The data obtained in this study demonstrate that the concentration of serotonin is markedly elevated (18to 27-fold) at the site of a coronary arterial stenosis in open-chest, anesthetized dogs with cyclic flow variations. Cyclic flow variations in this experimental preparation were abolished by ketanserin, a 5-hydroxytryptamine antagonist, but serotonin concentration at the site of the coronary stenosis remained elevated. The intra-atrial administration of serotonin (0.16 to 1 mg/min) restored cyclic flow variations after they had been abolished by ketanserin. Taken together, these data suggest that serotonin may be one of the important mediators of cyclic flow variations in this experimental preparation.
(R4 1 468, 3-(2-[4-(4-fluorbenzoyl)-1 -piperidinyl ethyll-2,4(1H,3H)-quinazolinedione, Janssen Pharmaceutical, Beerse, Belgium), a 5-hydroxytryptamine antagonist, usually eliminates CFVs in the canine preparation with a proximal coronary arterial constriction. 3 In the same studies, we also demonstrated that prazosin (0.01 mg/kg), an ac-adrenergic antagonist, and propranolol (1 to 2 mg/kg), a ,3-adrenergic antagonist, were ineffective in altering CFV frequency,3 and that yohimbine, an b2-adrenergic antagonist, reduced the frequency of CFVs but was not as effective as ketanserin. Ketanserin was effective in eliminating CFVs but it was unclear whether this protective effect was related primarily to blockade of serotonin receptors. In the present study, we tested the hypothesis that serotonin may be one of the important mediators of CFVs in stenotic canine coronary arteries. The tissue concentration of serotonin was determined in both normal canine coronary arterial segments and in stenotic canine coronary arterial segments in which CFVs had occurred. The concentration of serotonin was determined in the same coronary arteries in a separate group of dogs in which CFVs were abolished by ketanserin. Furthermore, the role of serotonin in mediating CFVs was determined by establishing CFVs in another group of dogs, eliminating them with ketanserin, and subsequently infusing serotonin directly into the left atrium to determine whether CFVs could be restored by displacing ketanserin from its receptor site with excess of the agonist.
Methods
Forty-three male mongrel dogs (22 to 34 kg) were anesthetized with sodium pentobarbital (30 mg/kg iv) and ventilated with room air on a Harvard respirator. Tidal volume and respiratory rate were adjusted to maintain blood gases and pH within physiologic limits. Arterial and venous catheters were inserted into a common carotid artery and a jugular vein for measurement of systemic arterial pressure and administration of intravenous fluid or drug, respectively. Heating pads were placed under the animals to maintain rectal temperatures between 370 and 390 C. A thoracotomy was performed in the fifth left intercostal space, and the heart was suspended in a pericardial cradle. A segment of the left anterior descending coronary artery (LAD) was dissected free from surrounding tissue and a pulsed Doppler flow probe (manufactured by Dr. C. J. Hartley, Houston)8 was placed around the LAD proximal to the area to be constricted (figure 1).
After instrumentation was completed, animals were permitted to stabilize for 30 min. Control hemodynamic measurements, including heart rate, systemic arterial pressure, and mean and phasic coronary blood flow velocity, were recorded continuously on a Hewlett-Packard (Model 7758) eight-channel recorder. A hard plastic cylindrical constrictor was placed around the LAD, with a lumen diameter that was required to attenuate reactive hyperemia after 10 sec of total coronary arterial occlusion (figure l).3 4 Once the CFVs were established, they were observed for 30 min. During this period, CFV frequency, phasic and mean coronary blood flow velocity, and systemic hemodynamics were recorded. Changes in coronary arterial flow velocity were related to baseline blood flow velocity through the coronary artery before constriction. In ketanserin-treated dogs, serotonin significantly increased the flow velocity before reinitiation of CFVs. In these dogs (group 1II below), coronary flow velocity changes after CFV restoration with serotonin were compared with flow velocity during infusion of serotonin but before reinitiation of CFVs. With this experimental preparation, the following animals were studied. Group I dogs. Twelve dogs were killed after 30 min of CFVs. Normal circumflex and proximal and stenosed LAD coronary segments were obtained for the subsequent measurement of serotonin. Group II dogs. Ketanserin (Janssen Pharmaceutical, Beerse, Belgium) was administered through a left atrial catheter to abolish CFVs in 13 dogs. The dose of ketanserin required to abolish CFVs averaged 0.96 + 0.23 mg/kg (range 0.25 to 3 mg/kg). Thirty minutes after abolition of CFVs, these animals were killed and coronary arterial segments were removed for subsequent measurements of serotonin.
Group III dogs. In seven dogs (group II-A) instrumented as described above, ketanserin (0.61 -+-0. 1 1 mg/kg) was administered to abolish CFVs. One hour after CFVs were abolished with ketanserin, serotonin was infused intra-atrially at a constant rate beginning at a dose of 0.25 mg/min and increasing to 0.5, 1, and 2.5 mg/min at 15 min intervals until CFVs were restored. Once a serotonin infusion rate was identified that restored CFVs, the infusion was continued while hemodynamics, CFV frequency, and phasic and mean coronary flow velocities were documented for another 30 min period. There was a significant depression of mean arterial pressure at the infusion rate of serotonin that restored CFVs (1.64 + 0.3 mg/min).
To eliminate this decline in blood pressure as a potential cause for changes in coronary flow, an adjustable constrictor was placed around the descending aorta in six additional dogs (group Ill-B). After the initial 30 min of CFVs, ketanserin (0.5 mg/kg) was administered intra-atrially to eliminate CFVs. Once serotonin infusion was begun, mean arterial pressure was maintained at approximately the same level as measured after administration of ketanserin by adjustment of the aortic constrictor device.
In five additional dogs (group Ill-C), serotonin was infused into the left atrium beginning at 0.1 mg/min. These serotonin concentrations (average infusion rate of 0. 16 + 0.04 mg/min) did not decrease systemic arterial pressure significantly in comparison to that present after ketanserin had abolished the CFVs (average ketanserin dose = 1.25 + 0.3 mg/kg). Measurement of serotonin. In the 25 dogs that did not receive exogenous serotonin, segments of the LAD and the circumflex coronary artery were dissected free of surrounding connective tissue, removed from the heart, rinsed gently in normal saline, and divided. Segments of normal circumflex, LAD proximal to the constrictor and flow probe, and LAD underneath the constrictor were separated and rapidly frozen at -700 C.
The segments of vascular tissue for serotonin measurement were weighed (wet weight) and homogenized in 500 gl of 0.05M sodium phosphate buffer, pH 7.2, with a polytron homogenizer. Each sample was centrifuged at 28,000 x g for 20 min at 40 C, and the supernatant was collected for assay. Serotonin concentrations were measured by a modified method of Hussain and Sole9 as described below. With this method, serotonin was converted to N-acetyl serotonin by acetic anhydride. In the next step, N-acetyl serotonin was converted to radioactive melatonin by incubating with hydroxyindole-O-methyltransferase and tritiated S-adenosyl methionine. The radioactive melatonin was extracted, purified by thin-layer chromatography, and counted. The modifications of the assay were as follows. The crude hydroxyindole-O-methyltransferase was prepared from pineal glands and then further purified by Sephadex-gel (G-200) chromatography to obtain the pure enzyme, which was stored lyophilized in small (300 to 500 ,ul) aliquots. During reconstitution of the enzyme, 0.1 % bovine albumin containing 1 unit of aprotinin/ml was used to ensure the stability of the purified enzyme used in the assay. During the acetylation stage, the excess acetic anhydride present was evaporated at 440 C in a Savant vacuum centrifuge (Savant Instruments, Hicksville, NY) under high vacuum (<200 millitorr) for 10 min. This removed all the acetic anhydride without degrading any of the formed N-acetyl-serotonin. These modifications improved the sensitivity of the assay to 2 pg of serotonin and the interassay coefficient of variation to 3.75%. The serotonin concentration was expressed as nanograms per gram of vascular tissue. Statistical analyses. Values are expressed as mean + SEM. A one-way analysis of variance (ANOVA) was used in groups I and II dogs to determine whether significant differences existed among the serotonin concentrations from three different locations: circumflex, proximal LAD, and stenosed LAD. A twoway ANOVA with Duncan's multiple range test was used to determine whether there were significant differences in serotonin concentrations between untreated and ketanserin-treated dogs in coronary arterial segments from the same locations. Hemodynamic variables in group III dogs were analyzed with a repeated-measures ANOVA procedure. A p value <.05 was considered statistically significant.
Results
Forty-three of 44 dogs developed CFVs after placement of a coronary constrictor. The constrictor reduced mean coronary blood flow velocity to 67 + 4% of control and eliminated the hyperemic response to total brief coronary occlusion. Peak diastolic blood flow velocity (termed phasic blood flow velocity) was reduced to 54 + 3% of control values. This reduction in flow corresponds roughly to an 80% to 90% reduction in luminal cross-sectional area.
Hemodynamic changes. Hemodynamic data in the 12 group I dogs that had CFVs for at least 30 min before death are shown in table 1. Baseline systemic arterial pressures and heart rates before generation of CFVs were not significantly different from those recorded after 30 min of CFVs. Hemodynamics in the 13 group II dogs are also shown in table 1. Baseline systemic arterial pressures and heart rates were stable during the control period and during 30 min of CFVs. After the administration of ketanserin, heart rates and blood pressures declined significantly and remained at that level for the duration of the study.
Hemodynamics were stable in the 18 group III dogs from the initial stabilization period through 1 hr of CFVs as shown in table 2. The administration of ketanserin resulted in bradycardia and a decrease in blood pressure. When serotonin was infused into the left atrium after abolition of CFVs with ketanserin, a significant decline in mean arterial blood pressure occurred in group III-A dogs due primarily to a decline in diastolic blood pressure. However, the use of an aortic constrictor permitted mean aortic pressure to be maintained at postketanserin levels in the upper body in group 111-B dogs.
In group III-A dogs given relatively larger doses of serotonin without control of blood pressure, systemic blood pressure declined significantly with infusion of serotonin after ketanserin abolished CFVs (table 2). In group III-C dogs that received relatively small doses of serotonin, systemic arterial blood pressure did not change significantly after serotonin as compared with values present after ketanserin (table 2) .
CFV frequency and severity. The frequency of CFVs in group I dogs was 1 1.9 cycles/hr (table 1). The severity of the cyclic flows, measured by nadir of flow Values expressed as mean ± SEM. AOD = aortic diastolic pressure; AOM aortic mean pressure; AOS = aortic systolic pressure; HR = heart rate; PHFphasic or peak diastolic coronary blood flow velocity; MNF = mean coronary blood flow velocity (both PHF and MNF are expressed as a percent of respective control blood flow before placement of the constrictor).
AValue is significantly different from original control value, p < .05. ceived 0.5 mg/kg, two received 1 mg/kg, two received 2 mg/kg, and one received 3 mg/kg before CFVs were abolished.
The frequency of CFVs during the initial period and after serotonin-induced restoration following administration of ketanserin were not significantly different in any of the three subgroups of group III dogs. Severity of CFVs, measured by mean and phasic flow velocities at flow nadir, also were similiar for the initial period of CFVs and the serotonin-restored CFVs in all group I dogs (table 2). Figure 2 illustrates the frequency ar severity of CFVs from group 111-B dogs.
Serotonin concentrations in coronary arteries. Ser tonin concentrations measured in the area of the LA stenosis in untreated dogs were 18-fold higher ththose measured in the LAD proximal to the stenos and in the undisturbed circumflex coronary artery (23 + 72, 13.3 3, and 7.4 1.2 ng/g tissue, respe tively, figure 3, p < .0004). Serotonin concentratioi 576 in stenosed LADs in which CFVs had been abolished with ketanserin were 27-fold higher than those in segments from the proximal LAD above the coronary constrictor and in the circumflex coronary artery (320 + 73, 12 + 2, and 9 ± 1 ng/g tissue, respectively, figure 3, p < .001). The elevated serotonin concentrations in group I dogs were not significantly different than those measured in the group II dogs. There was no correlation between the dose of ketanserin required to abolish CFVs and the measured serotonin concentrations in the constricted vessels (r = .42, p = NS). Some variation was observed in coronary arterial serotonin concentrations in normal segments of the in LAD and circumflex coronary arteries in both untreated and ketanserin-treated dogs (range of values was 0.7 to 45 ng/g tissue in untreated animals and 0. 1 to 27.1 ng/g tissue in ketanserin-treated animals). Considerably greater variation was observed in serotonin concentrations in constricted LAD segments in both group I and II dogs. Group I dogs had a range of serotonin concentrations from 13.6 to 726 ng/g tissue (mean 237.8 + 71.8), whereas group II dogs had values that ranged from 37 to 907 ng/g tissue (mean 320 ± 73) in stenosed LAD segments.
Discussion
The results of this present study suggest that serotonin may be a mediator of transient flow alterations Serotonin is accumulated by platelets by both active transport and passive diffusion from circulating plasma and is stored in dense granules within the platelets.6, 10 Irreversible platelet aggregation occurs when activated platelets release stored serotonin, thromboxane A2, other cyclooxygenase and lipoxygenase products, and ADP.1'12 It has been suggested that serotonin initiates a preliminary event during early platelet activation common to all three pathways of platelet aggregation.5' 12 Platelet aggregates at the site of endothelial injury associated with the coronary stenosis are likely to be the original source for the elevated serotonin concentrations observed in the study. 14 Ketanserin, a selective serotonin receptor antagonist in platelets and vascular tissue, competitively inhibits direct activation of platelets by serotonin.' 6 13 14 17 The effective dose of ketanserin that restored a normal flow pattern through coronary arteries was variable in the present study. It is possible that the severity of the stenosis, the configuration of the stenosis, the degree of endothelial damage, or variations in platelet reactivity contribute to this variability. Additionally, there may be some relationship between drug potency and drug age when ketanserin is stored in powder form, since recently received ketanserin appears to be more potent than ketanserin that has been stored for 3 months or longer. However, none of these possibilities has been explored systematically. Elevated serotonin concentrations were also observed in the coronary arterial segments removed from the site of stenosis in those animals in which CFVs were abolished with ketanserin. Both untreated and ketanserin-treated animals had a layer of platelets adhered to the vascular subendothelium at the stenotic site where the original platelet aggregation and/or vasoconstriction occurred resulting in CFVs. The high concentrations of serotonin remaining after inhibition of CFVs with ketanserin suggest that this initial layer of platelets remains adherent and circulating platelets may still be activated, but ketanserin likely prevents serotonin receptor-mediated irreversible aggregation and/or local vasoconstriction and the consequent formation of a coronary thrombus. Ketanserin also may be preventing platelet aggregationmediated release of serotonin from dense granules in platelets, while not affecting uptake of serotonin into platelets, which is mediated by a separate receptor.5 ' 6 Blockade of platelet aggregation-induced release of serotonin has been observed in platelets treated with aspirin.'5 A similar mechanism may account for the trend toward higher serotonin levels in ketanserintreated stenotic coronary arteries, although these serotonin concentrations were not significantly higher than Vol. 73, No. 3, March 1986 those measured in untreated stenotic coronary arteries.
Presumably, ketanserin antagonizes the ability of serotonin to amplify the effect of other mediators on platelet aggregation,'6 thus interrupting CFVs even in the presence of very elevated tissue serotonin concentration. Alternatively, ketanserin may modulate the effects of serotonin on coronary vascular smooth muscle.'7 The vascular effects of serotonin in large coronary arteries are mediated primarly by 5-HT2 receptors. 16' 1" Vascular effects of serotonin include arterial and venous smooth muscle contraction, arteriolar dilatation, and inhibition of peripheral adrenergic neurotransmission. 16 The effect of infused serotonin observed in an intact organism is determined by the relative balance between its vasoconstrictor and vasodilator actions, its rate of infusion, and its rate of inactivation, primarily by the lung, and potentially by the presence or absence of an intact vascular endothelium. 16' 1 Rapid intravenous infusion of ketanserin significantly decreases systemic arterial blood pressure, as observed in this study.19' 20 When serotonin was infused after 5-HT2 receptor blockade, it produced vasodilation.'7' 21 The mechanism of this serotonin-induced vasodilation is incompletely understood. 16 Serotonin successfully restored CFVs after ketanserin blockade; however, it also resulted in systemic hypotension caused by peripheral vasodilation. In six group III-B dogs that received exogenous serotonin after ketanserin, blood pressure was maintained with an aortic constrictor and CFVs were restored. In other animals, serotonin restored CFVs irrespective of whether systemic blood pressure changed substantially. Thus serotonin is capable of reinitiating CFVs in this preparation.
In conclusion, the results from this study suggest that serotonin may be a mediator of CFVs in this experimental preparation. Whether similar relationships between spontaneous alterations in coronary blood flow and serotonin concentration at sites of coronary arterial stenosis exist in human beings needs to be determined.
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